High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas
Gespeichert in:
| Veröffentlicht in: | Blood 2022-11, Vol.140 (Supplement 1), p.1183-1184 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1184 |
|---|---|
| container_issue | Supplement 1 |
| container_start_page | 1183 |
| container_title | Blood |
| container_volume | 140 |
| creator | Nieto, Yago Valdez, Benigno C Thall, Peter F Ramdial, Jeremy L. Srour, Samer A Hosing, Chitra Saini, Neeraj Alousi, Amin M Qazilbash, Muzaffar H Popat, Uday R Gulbis, Alison Shigle, Terri Lynn Bassett, Roland Guillermo-Pacheco, Maria Ledesma, Celina Strati, Paolo Ahmed, Sairah Steiner, Raphael Westin, Jason Nair, Ranjit Iyer, Swaminathan P. Champlin, Richard E Shpall, Elizabeth J Andersson, Borje S |
| description | |
| doi_str_mv | 10.1182/blood-2022-156121 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1182_blood_2022_156121</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S000649712202033X</els_id><sourcerecordid>S000649712202033X</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1851-7b23485f37382020219dba68acff10129223f6531edbaab7d9077909a01814693</originalsourceid><addsrcrecordid>eNp9kN1KwzAUgIMoOKcP4N15gWhOuv7h1ajTDQYbc16XNE3WSNuUpFP6Ej6znfPaqwMHvo9zPkLukT0gJvyxqK0tKWecUwwj5HhBJhjyhDLG2SWZMMYiOktjvCY33n8whrOAhxPyvTSHChZaGynkAFZDXynYzndbWLWVKUxvHWxq0QlnCshsU5hWlfBl-gpOKH22XkFWqcaOoBPdAKItYX7sbW0P9ujhrVcNzVRdw96J1ne1aHvQo3WntBNy9A-wHpquso3wt-RKi9qru785Je8vi322pOvN6yqbr6nEJEQaFzyYJaEO4iAZf2Yc07IQUSKk1siQp5wHOgoDVONaFHGZsjhOWSoYJjiL0mBK8OyVznrvlM47ZxrhhhxZfgqa_wbNT0Hzc9CReTozajzs0yiXe2lUK1VpnJJ9XlrzD_0DVh1-rw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Nieto, Yago ; Valdez, Benigno C ; Thall, Peter F ; Ramdial, Jeremy L. ; Srour, Samer A ; Hosing, Chitra ; Saini, Neeraj ; Alousi, Amin M ; Qazilbash, Muzaffar H ; Popat, Uday R ; Gulbis, Alison ; Shigle, Terri Lynn ; Bassett, Roland ; Guillermo-Pacheco, Maria ; Ledesma, Celina ; Strati, Paolo ; Ahmed, Sairah ; Steiner, Raphael ; Westin, Jason ; Nair, Ranjit ; Iyer, Swaminathan P. ; Champlin, Richard E ; Shpall, Elizabeth J ; Andersson, Borje S</creator><creatorcontrib>Nieto, Yago ; Valdez, Benigno C ; Thall, Peter F ; Ramdial, Jeremy L. ; Srour, Samer A ; Hosing, Chitra ; Saini, Neeraj ; Alousi, Amin M ; Qazilbash, Muzaffar H ; Popat, Uday R ; Gulbis, Alison ; Shigle, Terri Lynn ; Bassett, Roland ; Guillermo-Pacheco, Maria ; Ledesma, Celina ; Strati, Paolo ; Ahmed, Sairah ; Steiner, Raphael ; Westin, Jason ; Nair, Ranjit ; Iyer, Swaminathan P. ; Champlin, Richard E ; Shpall, Elizabeth J ; Andersson, Borje S</creatorcontrib><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2022-156121</identifier><language>eng</language><publisher>Elsevier Inc</publisher><ispartof>Blood, 2022-11, Vol.140 (Supplement 1), p.1183-1184</ispartof><rights>2022 The American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1851-7b23485f37382020219dba68acff10129223f6531edbaab7d9077909a01814693</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Nieto, Yago</creatorcontrib><creatorcontrib>Valdez, Benigno C</creatorcontrib><creatorcontrib>Thall, Peter F</creatorcontrib><creatorcontrib>Ramdial, Jeremy L.</creatorcontrib><creatorcontrib>Srour, Samer A</creatorcontrib><creatorcontrib>Hosing, Chitra</creatorcontrib><creatorcontrib>Saini, Neeraj</creatorcontrib><creatorcontrib>Alousi, Amin M</creatorcontrib><creatorcontrib>Qazilbash, Muzaffar H</creatorcontrib><creatorcontrib>Popat, Uday R</creatorcontrib><creatorcontrib>Gulbis, Alison</creatorcontrib><creatorcontrib>Shigle, Terri Lynn</creatorcontrib><creatorcontrib>Bassett, Roland</creatorcontrib><creatorcontrib>Guillermo-Pacheco, Maria</creatorcontrib><creatorcontrib>Ledesma, Celina</creatorcontrib><creatorcontrib>Strati, Paolo</creatorcontrib><creatorcontrib>Ahmed, Sairah</creatorcontrib><creatorcontrib>Steiner, Raphael</creatorcontrib><creatorcontrib>Westin, Jason</creatorcontrib><creatorcontrib>Nair, Ranjit</creatorcontrib><creatorcontrib>Iyer, Swaminathan P.</creatorcontrib><creatorcontrib>Champlin, Richard E</creatorcontrib><creatorcontrib>Shpall, Elizabeth J</creatorcontrib><creatorcontrib>Andersson, Borje S</creatorcontrib><title>High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas</title><title>Blood</title><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kN1KwzAUgIMoOKcP4N15gWhOuv7h1ajTDQYbc16XNE3WSNuUpFP6Ej6znfPaqwMHvo9zPkLukT0gJvyxqK0tKWecUwwj5HhBJhjyhDLG2SWZMMYiOktjvCY33n8whrOAhxPyvTSHChZaGynkAFZDXynYzndbWLWVKUxvHWxq0QlnCshsU5hWlfBl-gpOKH22XkFWqcaOoBPdAKItYX7sbW0P9ujhrVcNzVRdw96J1ne1aHvQo3WntBNy9A-wHpquso3wt-RKi9qru785Je8vi322pOvN6yqbr6nEJEQaFzyYJaEO4iAZf2Yc07IQUSKk1siQp5wHOgoDVONaFHGZsjhOWSoYJjiL0mBK8OyVznrvlM47ZxrhhhxZfgqa_wbNT0Hzc9CReTozajzs0yiXe2lUK1VpnJJ9XlrzD_0DVh1-rw</recordid><startdate>20221115</startdate><enddate>20221115</enddate><creator>Nieto, Yago</creator><creator>Valdez, Benigno C</creator><creator>Thall, Peter F</creator><creator>Ramdial, Jeremy L.</creator><creator>Srour, Samer A</creator><creator>Hosing, Chitra</creator><creator>Saini, Neeraj</creator><creator>Alousi, Amin M</creator><creator>Qazilbash, Muzaffar H</creator><creator>Popat, Uday R</creator><creator>Gulbis, Alison</creator><creator>Shigle, Terri Lynn</creator><creator>Bassett, Roland</creator><creator>Guillermo-Pacheco, Maria</creator><creator>Ledesma, Celina</creator><creator>Strati, Paolo</creator><creator>Ahmed, Sairah</creator><creator>Steiner, Raphael</creator><creator>Westin, Jason</creator><creator>Nair, Ranjit</creator><creator>Iyer, Swaminathan P.</creator><creator>Champlin, Richard E</creator><creator>Shpall, Elizabeth J</creator><creator>Andersson, Borje S</creator><general>Elsevier Inc</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20221115</creationdate><title>High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas</title><author>Nieto, Yago ; Valdez, Benigno C ; Thall, Peter F ; Ramdial, Jeremy L. ; Srour, Samer A ; Hosing, Chitra ; Saini, Neeraj ; Alousi, Amin M ; Qazilbash, Muzaffar H ; Popat, Uday R ; Gulbis, Alison ; Shigle, Terri Lynn ; Bassett, Roland ; Guillermo-Pacheco, Maria ; Ledesma, Celina ; Strati, Paolo ; Ahmed, Sairah ; Steiner, Raphael ; Westin, Jason ; Nair, Ranjit ; Iyer, Swaminathan P. ; Champlin, Richard E ; Shpall, Elizabeth J ; Andersson, Borje S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1851-7b23485f37382020219dba68acff10129223f6531edbaab7d9077909a01814693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nieto, Yago</creatorcontrib><creatorcontrib>Valdez, Benigno C</creatorcontrib><creatorcontrib>Thall, Peter F</creatorcontrib><creatorcontrib>Ramdial, Jeremy L.</creatorcontrib><creatorcontrib>Srour, Samer A</creatorcontrib><creatorcontrib>Hosing, Chitra</creatorcontrib><creatorcontrib>Saini, Neeraj</creatorcontrib><creatorcontrib>Alousi, Amin M</creatorcontrib><creatorcontrib>Qazilbash, Muzaffar H</creatorcontrib><creatorcontrib>Popat, Uday R</creatorcontrib><creatorcontrib>Gulbis, Alison</creatorcontrib><creatorcontrib>Shigle, Terri Lynn</creatorcontrib><creatorcontrib>Bassett, Roland</creatorcontrib><creatorcontrib>Guillermo-Pacheco, Maria</creatorcontrib><creatorcontrib>Ledesma, Celina</creatorcontrib><creatorcontrib>Strati, Paolo</creatorcontrib><creatorcontrib>Ahmed, Sairah</creatorcontrib><creatorcontrib>Steiner, Raphael</creatorcontrib><creatorcontrib>Westin, Jason</creatorcontrib><creatorcontrib>Nair, Ranjit</creatorcontrib><creatorcontrib>Iyer, Swaminathan P.</creatorcontrib><creatorcontrib>Champlin, Richard E</creatorcontrib><creatorcontrib>Shpall, Elizabeth J</creatorcontrib><creatorcontrib>Andersson, Borje S</creatorcontrib><collection>CrossRef</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nieto, Yago</au><au>Valdez, Benigno C</au><au>Thall, Peter F</au><au>Ramdial, Jeremy L.</au><au>Srour, Samer A</au><au>Hosing, Chitra</au><au>Saini, Neeraj</au><au>Alousi, Amin M</au><au>Qazilbash, Muzaffar H</au><au>Popat, Uday R</au><au>Gulbis, Alison</au><au>Shigle, Terri Lynn</au><au>Bassett, Roland</au><au>Guillermo-Pacheco, Maria</au><au>Ledesma, Celina</au><au>Strati, Paolo</au><au>Ahmed, Sairah</au><au>Steiner, Raphael</au><au>Westin, Jason</au><au>Nair, Ranjit</au><au>Iyer, Swaminathan P.</au><au>Champlin, Richard E</au><au>Shpall, Elizabeth J</au><au>Andersson, Borje S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas</atitle><jtitle>Blood</jtitle><date>2022-11-15</date><risdate>2022</risdate><volume>140</volume><issue>Supplement 1</issue><spage>1183</spage><epage>1184</epage><pages>1183-1184</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><pub>Elsevier Inc</pub><doi>10.1182/blood-2022-156121</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-4971 |
| ispartof | Blood, 2022-11, Vol.140 (Supplement 1), p.1183-1184 |
| issn | 0006-4971 1528-0020 |
| language | eng |
| recordid | cdi_crossref_primary_10_1182_blood_2022_156121 |
| source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| title | High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T18%3A21%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High%20Efficacy%20of%20the%20PARP%20Inhibitor%20Olaparib%20Combined%20with%20High-Dose%20Chemotherapy%20and%20Autologous%20Stem-Cell%20Transplant%20for%20Refractory%20Lymphomas&rft.jtitle=Blood&rft.au=Nieto,%20Yago&rft.date=2022-11-15&rft.volume=140&rft.issue=Supplement%201&rft.spage=1183&rft.epage=1184&rft.pages=1183-1184&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2022-156121&rft_dat=%3Celsevier_cross%3ES000649712202033X%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S000649712202033X&rfr_iscdi=true |